

Reference

I-269

1. C Zaidman, C Proudman, C McDonald et al. P.129 One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD. *Neuromuscular disorders*. 2022;32:S101.
2. JR Mendell Z Sahenk, KJ Lehman et al. Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: A 4-year update. 27th International Annual Congress of the World Muscle Society, Halifax, Canada.